Time to next exacerbation · adults and children with cystic fibrosis (during acute exacerbations of lung disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · adults and children with cystic fibrosis (during acute exacerbations of lung disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
FVC (% predicted) Change from baseline · adults and children with cystic fibrosis (during acute exacerbations of lung disease)
1 finding from 1 review
Time to next exacerbation · adults and children with cystic fibrosis (during acute exacerbations of lung disease)
1 finding from 1 review
Quality of life · adults and children with cystic fibrosis (during acute exacerbations of lung disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
FVC (% predicted) Change from baseline · adults and children with cystic fibrosis (during acute exacerbations of lung disease)
1 finding from 1 review
Time to next exacerbation · adults and children with cystic fibrosis (during acute exacerbations of lung disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · adults and children with cystic fibrosis (during acute exacerbations of lung disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis (during acute exacerbations of lung disease)
1 finding from 1 review
FVC (% predicted) Change from baseline · adults and children with cystic fibrosis (during acute exacerbations of lung disease)
1 finding from 1 review
Intervention not reported
Exercise capacity · patients with pulmonary hypertension secondary to systemic scleroderma.
1 finding from 1 review
no estimate extracted
67 participants
Very low
Intervention not reported
WHO/NYHA functional class · patients with pulmonary hypertension secondary to systemic scleroderma.
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Exacerbations (number of people experiencing ≥ 1 exacerbations) · patients with chronic obstructive pulmonary disease
Indacaterol showed no clear difference in number of participants experiencing at least 1 exacerbation… compared with twice‐daily long‐acting beta2‐agonists (moderate certainty).
1 finding from 1 review
Serious adverse events Adverse events · patients with chronic obstructive pulmonary disease
Indacaterol showed no clear difference in serious adverse events Adverse events compared with twice‐daily long‐acting beta2‐agonists (moderate certainty).
1 finding from 1 review
Mortality Deaths · patients with chronic obstructive pulmonary disease
Indacaterol showed no clear difference in mortality Deaths compared with twice‐daily long‐acting beta2‐agonists (moderate certainty).
1 finding from 1 review
FEV1 · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Quality of life: number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score · patients with chronic obstructive pulmonary disease
Indacaterol showed no clear difference in number of participants with a clinically significant improvement in… compared with twice‐daily long‐acting beta2‐agonists (moderate certainty).
1 finding from 1 review
Improvement in symptoms: number of participants with clinically significant improvement: using TDI focal score (≥ 1 unit) · patients with chronic obstructive pulmonary disease
Indacaterol showed no clear difference in number of participants with a clinically significant improvement in… compared with twice‐daily long‐acting beta2‐agonists (moderate certainty).
1 finding from 1 review
Overall survival (OS) · non‐small cell lung cancer in the elderly population
Non‐platinum single‐agent may leads to lower overall survival (OS) compared with non‐platinum combination treatment (low certainty).
1 finding from 1 review
1‐Year survival rate · non‐small cell lung cancer in the elderly population
Non‐platinum therapies probably leads to lower 1‐Year survival rate compared with platinum combination (moderate certainty).
1 finding from 1 review